Rational design of highly potent SARS-CoV-2 nsp14 methyltransferase inhibitors

13 March 2023, Version 1


The search for new drugs against COVID-19 and its causative agent, SARS-CoV-2, is one of the major trends in current medicinal chemistry. Targeting capping machinery could be one of therapeutic concepts based on a unique mechanism of action. Viral RNA cap synthesis involves two methylation steps, the first of which is mediated by the nsp14 protein. Here, we rationally designed and synthesized a series of compounds capable of binding to both the S-adenosyl-L-methionine and the RNA binding site of SARS-CoV-2 nsp14 7-N methyltransferase. These hybrid molecules exerted excellent potency, high selectivity towards various human methyltransferases, they are nontoxic and highly cell permeable. Despite the outstanding activity against the enzyme, our compounds showed poor antiviral performance in vitro. This suggests that the activity of this viral methyltransferase is mainly associated with immune response. Our compounds represent unique tools to further explore the role of the SARS-CoV-2 nsp14 methyltransferase in viral replication.


antiviral compounds
RNA capping

Supplementary materials

Supporting Information
Supporting Information: Synthetic procedures, methods for MTase, antiviral and cytotoxicity assays, docking studies. Supporting tables. 1H and 13C NMR of final analogues.


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.